- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06686394
Estudio de patritumab deruxtecan con otros agentes anticancerígenos en participantes con cáncer de mama HER2 positivo que se ha diseminado y no se puede extirpar quirúrgicamente (MK-1022-009)
HERTHENA-Breast-01: un estudio de búsqueda de dosis, multicéntrico, abierto y de fase 1b/2 para evaluar la seguridad y la actividad antitumoral de patritumab deruxtecan en participantes con cáncer de mama localmente avanzado, irresecable, positivo para HER2 o cáncer de mama metastásico
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
Ontario
-
Kingston, Ontario, Canadá, K7L 2V7
- Reclutamiento
- Kingston General Hospital ( Site 0061)
-
Contacto:
- Study Coordinator
- Número de teléfono: 6135336541
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- Princess Margaret Cancer Centre ( Site 0001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Canadá, H3T 1E2
- Reclutamiento
- Jewish General Hospital ( Site 0003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 514-340-8222
-
Montreal, Quebec, Canadá, H2X 3E4
- Reclutamiento
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Contacto:
- Study Coordinator
- Número de teléfono: (514)890-8000 x20737
-
-
-
-
-
Seoul, Corea del Sur, 03080
- Reclutamiento
- Seoul National University Hospital ( Site 0030)
-
Contacto:
- Study Coordinator
- Número de teléfono: 82-2-2072-0850
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center ( Site 0031)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82-2-1688-7575
-
-
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Contacto:
- Study Coordinator
- Número de teléfono: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana-Farber Cancer Institute ( Site 0050)
-
Contacto:
- Study Coordinator
- Número de teléfono: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Reclutamiento
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Contacto:
- Study Coordinator
- Número de teléfono: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Reclutamiento
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Contacto:
- Study Coordinator
- Número de teléfono: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Inova Schar Cancer Institute ( Site 0051)
-
Contacto:
- Study Coordinator
- Número de teléfono: 571-472-4724
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus ( Site 0011)
-
Contacto:
- Study Coordinator
- Número de teléfono: 04-7776234
-
Petah Tikva, Israel, 4941492
- Reclutamiento
- Rabin Medical Center ( Site 0012)
-
Contacto:
- Study Coordinator
- Número de teléfono: +972-505533121
-
Ramat Gan, Israel, 5265601
- Reclutamiento
- Sheba Medical Center ( Site 0010)
-
Contacto:
- Study Coordinator
- Número de teléfono: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 467-8602
- Reclutamiento
- Nagoya City University Hospital ( Site 0020)
-
Contacto:
- Study Coordinator
- Número de teléfono: +81-52-851-5511
-
-
-
-
Camden
-
London, Camden, Reino Unido, NW1 2PG
- Reclutamiento
- University College London Hospital ( Site 0041)
-
Contacto:
- Study Coordinator
- Número de teléfono: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Reino Unido, G12 0YN
- Reclutamiento
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441413017000
-
-
London, City of
-
London, London, City of, Reino Unido, EC1A 7BE
- Reclutamiento
- St Bartholomew s Hospital ( Site 0040)
-
Contacto:
- Study Coordinator
- Número de teléfono: +442073777000
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Otros nombres:
Trastuzumab administered via IV infusion
Otros nombres:
Trastuzumab biosimilar administered via IV infusion
Otros nombres:
|
|
Experimental: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Otros nombres:
Trastuzumab administered via IV infusion
Otros nombres:
Trastuzumab biosimilar administered via IV infusion
Otros nombres:
Pertuzumab administered via IV infusion |
|
Experimental: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Otros nombres:
Trastuzumab administered via IV infusion
Otros nombres:
Trastuzumab biosimilar administered via IV infusion
Otros nombres:
Tucatinib administered as oral tablets |
|
Experimental: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Otros nombres:
Trastuzumab administered via IV infusion
Otros nombres:
Trastuzumab biosimilar administered via IV infusion
Otros nombres:
Pertuzumab administered via IV infusion |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Periodo de tiempo: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Periodo de tiempo: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Periodo de tiempo: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Periodo de tiempo: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Periodo de tiempo: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Periodo de tiempo: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Periodo de tiempo: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de la piel
- Enfermedades de los senos
- Enfermedades de la piel y del tejido conectivo
- Neoplasias de mama
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Trastuzumab
- pertuzumab
- tucatinib
- Patritumab deruxtecan
- Ogivri
- Altruzante
Otros números de identificación del estudio
- 1022-009
- MK-1022-009 (Otro identificador: MSD)
- jRCT2041250022 (Identificador de registro: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Identificador de registro: EU CT)
- U1111-1346-4321 (Identificador de registro: UTN)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .